Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00418249 |
Recruitment Status
: Unknown
Verified December 2006 by Rabin Medical Center.
Recruitment status was: Not yet recruiting
First Posted
: January 4, 2007
Last Update Posted
: January 4, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alopecia | Drug: AS101 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women |

- hair density
- Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,
- Self-administered satisfaction questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women in menopause, over 50 years of age.
- Clinically diagnosed for AGA, according to Ludwig scale I-II.
Exclusion Criteria:
- Women treated with chronic medications.
- Use of Minoxidil within 3 months prior to entering study.
- Women who have underwent hair transplantation.
- Use of drugs with androgenic or anti-androgenic effects.
- Any other type of hair loss.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00418249
Contact: Danny Ben Amitai, MD | 972-3-9253770 | ||
Contact: Raziel Lurie, MD | rlurie@bezeqint.net |
Israel | |
Not yet recruiting | |
Tel Aviv, Israel | |
Contact: Danny Ben Amitai 972-3-9253770 |
Principal Investigator: | Danny Ben-Amitai, M.D. | Rabin Medical Center |
ClinicalTrials.gov Identifier: | NCT00418249 History of Changes |
Other Study ID Numbers: |
#69 REV 00 |
First Posted: | January 4, 2007 Key Record Dates |
Last Update Posted: | January 4, 2007 |
Last Verified: | December 2006 |
Keywords provided by Rabin Medical Center:
Androgenetic Alopecia Telogen effluvium Chronic telogen effluvium Menopause Female Androgenetic Alopecia (FAGA) |
Additional relevant MeSH terms:
Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Ammonium trichloro(dioxoethylene-O,O'-)tellurate Adjuvants, Immunologic |
Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Antiviral Agents Anti-Infective Agents Radiation-Protective Agents Protective Agents |